Granissetrom Generis (Granisetron)

Granissetrom Generis is indicated for the prevention of nausea and vomiting in specific clinical settings.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Prevention of postoperative nausea and vomiting (PONV) following surgical procedures.
• Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated.
• Management of nausea associated with radiation therapy in oncology patients.
• Adjunctive therapy for nausea related to diagnostic procedures that involve emetogenic agents.

The safety profile of granisetron includes both common and less frequent adverse effects.

Common

• Headache, often mild to moderate in intensity.
• Constipation, presenting as reduced bowel movements.
• Diarrhea, typically transient and self‑limiting.
• Fatigue or drowsiness, especially after initial dosing.

Serious

• Severe allergic reaction (anaphylaxis) with rash, swelling, or breathing difficulty.
• Cardiac arrhythmia or QT interval prolongation, which may require ECG monitoring.

Before initiating Granissetrom Generis, clinicians should consider several precautionary measures to ensure safe use.

• Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Evaluate cardiac risk factors, including baseline ECG for QT interval assessment.
• Use cautiously in patients with electrolyte disturbances (e.g., hypokalemia, hypomagnesemia).
• Review concomitant medications that may prolong QT interval.
• Consider dose adjustment or monitoring in hepatic or renal impairment.
• Counsel pregnant or breastfeeding women, as safety data are limited.

Granisetron may interact with other drugs, influencing its efficacy or safety profile.

Avoid

• Concurrent use with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics).
• Combination with potent CYP3A4 inhibitors that could increase granisetron levels.

Use with caution

• Co‑administration with other antiemetics that also block 5‑HT3 receptors.
• Use alongside drugs that affect electrolyte balance, such as diuretics.
• Concomitant use with serotonergic agents (e.g., SSRIs) may increase risk of serotonin syndrome, though rare.